- Stocks Could Drift as Historic Rally Runs On
- Japan Exports Dip, Stimulus Effect May Be Waning
- As More Banks Fail, Private Investors Gaining Favor
- Mounting Debt Outlook Poses Threat to Obama's Agenda
- Why Bernanke May Take a Beating in the Senate—Again
- FAA Probes Southwest Over Unauthorized Parts: Report
- Toyota to Cut Capacity to Match Sales: Report
- How the Average Investor Can Play Hedge Funds—Sort of
- Health Care: Is Public Option 'Really' Off The Table?
- Redbox Gets Paramount on Board; What's Next for Hollywood's DVD Battle
- Don't Count on Consumers to Fuel Economy: Strategist
- Stock Picker: Bernanke's Reappointment 'Positive' for Markets
- Clunker Blues? You Aren't Alone.
- Pros Say: Markets to 'Tumble to Earth' in Next 2 Months
- Why Viacom's Paramount is Short on Cash and What's Wrong With Movie Marketing
- California's For Sale — on EBay!
- Funny Business Product of the Week
- Home Prices Up, Experts Down on Housing
- Singapore manufacturing jumps 12 percent in July
- Minn. contest spotlights wines from frozen north
- Officials: Energy companies want closed Ford plant
- Microsoft apologizes for changing race in photo
- Toyota to cut production capacity at Japan factory
- Air China sees first half profit more than double
- China Life first half profit up 15 percent
- Colonial BancGroup files for Chapter 11 protection
- Toys R Us to offer coupons in trade-in program
Text Size 
NEW YORK - Drugstore operator and pharmacy benefits manager CVS Caremark Corp. spent more than $2 million to lobby in the second quarter as the government looked into broader health care reform.
CVS Caremark lobbied on reforms of insurance and Medicare and Medicaid, access to drugs, generic versions of pharmaceuticals and biotech drugs, and coverage of cancer drugs. It also lobbied on issues related to prescription drug benefits, reimbursement for generic drugs and other bills related to drug rebates.
Besides Congress, CVS Caremark lobbied the Department of Health and Human Services, Centers for Medicare and Medicaid Services, Food and Drug Administration, and the Drug Enforcement Administration in the April-June period.
The company also lobbied on the Employee Free Choice Act, a much debated bill that intends to make it easier for unions to organize, as well as on food safety, medical equipment and laws intended to fight abuse of the cough medicine dextromethorphan, according to the form filed July 20 with the House clerk's office.
The Woonsocket, R.I.-based company also spent about $2 million on lobbying in the first three months of the year.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes